These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 29503329)
41. Biomarkers in Parkinson's disease (recent update). Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710 [TBL] [Abstract][Full Text] [Related]
42. Network Imaging in Parkinsonian and Other Movement Disorders: Network Dysfunction and Clinical Correlates. Niethammer M; Eidelberg D Int Rev Neurobiol; 2019; 144():143-184. PubMed ID: 30638453 [TBL] [Abstract][Full Text] [Related]
43. Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Saeed U; Compagnone J; Aviv RI; Strafella AP; Black SE; Lang AE; Masellis M Transl Neurodegener; 2017; 6():8. PubMed ID: 28360997 [TBL] [Abstract][Full Text] [Related]
44. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004 [TBL] [Abstract][Full Text] [Related]
45. Dopamine transporter imaging in essential tremor with and without parkinsonian features. Waln O; Wu Y; Perlman R; Wendt J; Van AK; Jankovic J J Neural Transm (Vienna); 2015 Nov; 122(11):1515-21. PubMed ID: 26133163 [TBL] [Abstract][Full Text] [Related]
48. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement. Derlin T; Afzal W; Wilke F; Apostolova I; Klutmann S; Meyer PT; Buhmann C; Hesse S; Buchert R Nuklearmedizin; 2010; 49(4):139-47. PubMed ID: 20502846 [TBL] [Abstract][Full Text] [Related]
49. Clinical utility of ( Wong D; Veitch P; Schembri G Intern Med J; 2018 Sep; 48(9):1132-1137. PubMed ID: 30182400 [TBL] [Abstract][Full Text] [Related]
50. The role of positron emission tomography imaging in movement disorders. Bohnen NI; Frey KA Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962 [TBL] [Abstract][Full Text] [Related]
51. Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. Ko JH; Lee CS; Eidelberg D J Cereb Blood Flow Metab; 2017 Feb; 37(2):683-693. PubMed ID: 26980757 [TBL] [Abstract][Full Text] [Related]
52. [Imaging diagnosis of dementia]. Ishii K Nihon Rinsho; 2014 Apr; 72(4):681-6. PubMed ID: 24796097 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders. Fallahi B; Esmaeili A; Beiki D; Oveisgharan S; Noorollahi-Moghaddam H; Erfani M; Tafakhori A; Rohani M; Fard-Esfahani A; Emami-Ardekani A; Geramifar P; Eftekhari M Ann Nucl Med; 2016 Feb; 30(2):153-62. PubMed ID: 26612262 [TBL] [Abstract][Full Text] [Related]
55. Imaging in Parkinson's Disease. Politis M; Pagano G; Niccolini F Int Rev Neurobiol; 2017; 132():233-274. PubMed ID: 28554409 [TBL] [Abstract][Full Text] [Related]
56. The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes. Georgiopoulos C; Davidsson A; Engström M; Larsson EM; Zachrisson H; Dizdar N J Neurol; 2015 Sep; 262(9):2154-63. PubMed ID: 26122543 [TBL] [Abstract][Full Text] [Related]
57. Molecular imaging in Parkinsonism: The essential for clinical practice and future perspectives. Horowitz T; Grimaldi S; Azulay JP; Guedj E Rev Neurol (Paris); 2022 May; 178(5):484-489. PubMed ID: 35527085 [TBL] [Abstract][Full Text] [Related]
58. [Functional neuroimaging with SPECT in Parkinson's disease and Parkinsonisms]. Lorenzo-Bosquet C; Hernández-Vara J; Castell-Conesa J; Miquel-Rodríguez F Rev Neurol; 2008 Apr 1-15; 46(7):430-5. PubMed ID: 18389463 [TBL] [Abstract][Full Text] [Related]